Jennifer Adair, PhD

Jennifer Adair, PhD

Appointments

  • Assistant Member, Clinical Research Division
  • Research Assistant Professor, University of Washington

Education

  • Ph.D. Genetics and Cell Biology (Summa cum laude)
    Washington State University
    Pullman, WA
  • B.S. Chemistry (Cum laude)
    Youngstown State University
    Youngstown, Ohio

Awards and Honors

  • Executive Board of Directors – American Society of Gene and Cell Therapy (2018)
  • Hartwell Foundation Individual Biomedical Research Award (2018)
  • Human Gene Therapy Editorial Board (2017)
  • TEDx Healthcare Next Speaker (2017)
  • Outstanding New Investigator Award - American Society of Gene and Cell Therapy (2015)
  • Roche 454 High Throughput Sequencing Award - Fred Hutchinson Cancer Research Center (2012)
  • Young Investigator Award - International Society for Cell Therapy (2012) 
  • Abstract Excellence Award - American Society of Hematology (2011)
  • Travel Grant Award - Fanconi Anemia Research Fund (2011)
  • Travel Grant Award - American Society of Gene and Cell Therapy (2010-2011)
  • Excellence in Research Award - American Society of Gene and Cell Therapy (2010)
  • Finalist, Woman of the Year - Washington State University (2005)

Research Interests

  • Gene therapy in hematopoietic stem cells has emerged as a viable treatment for genetic, malignant and infectious diseases with the potential to significantly decrease global disease burden. However, the approach is unique to each disease target. The lessons learned from early clinical studies provide directives to overcome remaining barriers to mainstream clinical application of hematopoietic stem cell gene therapy.
  • General areas of development include refining stem cell populations targeted for gene transfer, improving efficiency and engraftment, and creation and validation of globally portable gene transfer protocols.
  • We use current state-of-the-art and newly developed technologies that bridge different scientific disciplines to translate gene therapy for each disease candidate into the most appropriate and widely available clinical approach.